Cargando…

Changes in correlation between promoter methylation and gene expression in cancer

BACKGROUND: Methylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation. Aberrant promoter methylation is considered a hallmark of cancer involved in silencing of tumor suppressor genes and activation of onco...

Descripción completa

Detalles Bibliográficos
Autores principales: Moarii, Matahi, Boeva, Valentina, Vert, Jean-Philippe, Reyal, Fabien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625954/
https://www.ncbi.nlm.nih.gov/pubmed/26510534
http://dx.doi.org/10.1186/s12864-015-1994-2
_version_ 1782398052542185472
author Moarii, Matahi
Boeva, Valentina
Vert, Jean-Philippe
Reyal, Fabien
author_facet Moarii, Matahi
Boeva, Valentina
Vert, Jean-Philippe
Reyal, Fabien
author_sort Moarii, Matahi
collection PubMed
description BACKGROUND: Methylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation. Aberrant promoter methylation is considered a hallmark of cancer involved in silencing of tumor suppressor genes and activation of oncogenes. However, recent studies have also challenged the simple model of gene expression control by promoter methylation in cancer, and the precise mechanism of and role played by changes in DNA methylation in carcinogenesis remains elusive. RESULTS: Using a large dataset of 672 matched cancerous and healthy methylomes, gene expression, and copy number profiles accross 3 types of tissues from The Cancer Genome Atlas (TCGA), we perform a detailed meta-analysis to clarify the interplay between promoter methylation and gene expression in normal and cancer samples. On the one hand, we recover the existence of a CpG island methylator phenotype (CIMP) with prognostic value in a subset of breast, colon and lung cancer samples, where a common subset of promoter CGIs hypomethylated in normal samples become hypermethylated. However, this hypermethylation is not accompanied by a decrease in expression of the corresponding genes, which are already lowly expressed in the normal genes. On the other hand, we identify tissue-specific sets of genes, different between normal and cancer samples, whose inter-individual variation in expression is significantly correlated with the variation in methylation of the 3’ flanking regions of the promoter CGIs. These subsets of genes are not the same in the different tissues, nor between normal and cancerous samples, but transcription factors are over-represented in all subsets. CONCLUSION: Our results suggest that epigenetic reprogramming in cancer does not contribute to cancer development via direct inhibition of gene expression through promoter hypermethylation. It may instead modify how the expression of a few specific genes, particularly transcription factors, are associated with DNA methylation variations in a tissue-dependent manner. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12864-015-1994-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4625954
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46259542015-10-30 Changes in correlation between promoter methylation and gene expression in cancer Moarii, Matahi Boeva, Valentina Vert, Jean-Philippe Reyal, Fabien BMC Genomics Research Article BACKGROUND: Methylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation. Aberrant promoter methylation is considered a hallmark of cancer involved in silencing of tumor suppressor genes and activation of oncogenes. However, recent studies have also challenged the simple model of gene expression control by promoter methylation in cancer, and the precise mechanism of and role played by changes in DNA methylation in carcinogenesis remains elusive. RESULTS: Using a large dataset of 672 matched cancerous and healthy methylomes, gene expression, and copy number profiles accross 3 types of tissues from The Cancer Genome Atlas (TCGA), we perform a detailed meta-analysis to clarify the interplay between promoter methylation and gene expression in normal and cancer samples. On the one hand, we recover the existence of a CpG island methylator phenotype (CIMP) with prognostic value in a subset of breast, colon and lung cancer samples, where a common subset of promoter CGIs hypomethylated in normal samples become hypermethylated. However, this hypermethylation is not accompanied by a decrease in expression of the corresponding genes, which are already lowly expressed in the normal genes. On the other hand, we identify tissue-specific sets of genes, different between normal and cancer samples, whose inter-individual variation in expression is significantly correlated with the variation in methylation of the 3’ flanking regions of the promoter CGIs. These subsets of genes are not the same in the different tissues, nor between normal and cancerous samples, but transcription factors are over-represented in all subsets. CONCLUSION: Our results suggest that epigenetic reprogramming in cancer does not contribute to cancer development via direct inhibition of gene expression through promoter hypermethylation. It may instead modify how the expression of a few specific genes, particularly transcription factors, are associated with DNA methylation variations in a tissue-dependent manner. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12864-015-1994-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-28 /pmc/articles/PMC4625954/ /pubmed/26510534 http://dx.doi.org/10.1186/s12864-015-1994-2 Text en © Moarii et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Moarii, Matahi
Boeva, Valentina
Vert, Jean-Philippe
Reyal, Fabien
Changes in correlation between promoter methylation and gene expression in cancer
title Changes in correlation between promoter methylation and gene expression in cancer
title_full Changes in correlation between promoter methylation and gene expression in cancer
title_fullStr Changes in correlation between promoter methylation and gene expression in cancer
title_full_unstemmed Changes in correlation between promoter methylation and gene expression in cancer
title_short Changes in correlation between promoter methylation and gene expression in cancer
title_sort changes in correlation between promoter methylation and gene expression in cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625954/
https://www.ncbi.nlm.nih.gov/pubmed/26510534
http://dx.doi.org/10.1186/s12864-015-1994-2
work_keys_str_mv AT moariimatahi changesincorrelationbetweenpromotermethylationandgeneexpressionincancer
AT boevavalentina changesincorrelationbetweenpromotermethylationandgeneexpressionincancer
AT vertjeanphilippe changesincorrelationbetweenpromotermethylationandgeneexpressionincancer
AT reyalfabien changesincorrelationbetweenpromotermethylationandgeneexpressionincancer